Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.33 Insider Own80.99% Shs Outstand248.65M Perf Week-7.35%
Market Cap4.28B Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float50.81M Perf Month0.31%
Income-595.68M PEG- EPS next Q0.04 Inst Own8.48% Short Float0.22% Perf Quarter68.42%
Sales61.90M P/S69.08 EPS this Y19.35% Inst Trans8.88% Short Ratio0.42 Perf Half Y61.62%
Book/sh-2.47 P/B- EPS next Y59.70% ROA-72.56% Short Interest0.11M Perf Year14.04%
Cash/sh0.26 P/C62.60 EPS next 5Y- ROE- 52W Range6.70 - 18.00 Perf YTD39.37%
Dividend Est.- P/FCF- EPS past 5Y- ROI-179.42% 52W High-11.11% Beta0.12
Dividend TTM- Quick Ratio0.78 Sales past 5Y0.00% Gross Margin-123.73% 52W Low138.81% ATR (14)0.58
Dividend Ex-Date- Current Ratio1.22 EPS Y/Y TTM-34835.82% Oper. Margin-582.12% RSI (14)57.84 Volatility4.52% 2.93%
Employees947 Debt/Eq- Sales Y/Y TTM- Profit Margin-962.30% Recom1.75 Target Price18.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-1936.71% Payout- Rel Volume0.65 Prev Close15.76
Sales Surprise- EPS Surprise-728.57% Sales Q/Q-6.63% EarningsNov 28 AMC Avg Volume270.49K Price16.00
SMA201.25% SMA5014.37% SMA20056.47% Trades Volume174,512 Change1.52%
Date Action Analyst Rating Change Price Target Change
Jan-29-24Upgrade Barclays Equal Weight → Overweight $10 → $17
Oct-20-23Upgrade Citigroup Sell → Neutral $5 → $10
Sep-21-23Initiated Barclays Equal Weight $10
Sep-07-22Initiated Morgan Stanley Equal-Weight $10
Sep-06-22Downgrade Citigroup Buy → Sell $12 → $5
Jul-26-22Initiated Citigroup Buy $12
Feb-29-24 04:05PM
Feb-26-24 09:58AM
Feb-23-24 08:15PM
Feb-15-24 06:30AM
04:00AM Loading…
Jan-29-24 04:00AM
Jan-22-24 10:03AM
Jan-19-24 11:30AM
Jan-10-24 03:30AM
Jan-03-24 03:30AM
Dec-29-23 04:05AM
Nov-29-23 04:00AM
Nov-28-23 04:15PM
Nov-21-23 08:00AM
07:00AM Loading…
Nov-14-23 07:00AM
Nov-10-23 09:30AM
Nov-07-23 08:00AM
Oct-12-23 04:00AM
Oct-05-23 01:21PM
Oct-03-23 08:29AM
Sep-25-23 04:00AM
Sep-20-23 04:30AM
Sep-11-23 05:00AM
Sep-05-23 09:30AM
Aug-30-23 04:15PM
Aug-29-23 05:00AM
Aug-22-23 09:15AM
Jul-31-23 04:00AM
01:30PM Loading…
Jul-26-23 01:30PM
Jul-24-23 04:00AM
Jul-06-23 07:26AM
Jun-28-23 07:00PM
Jun-12-23 07:00AM
May-31-23 05:20AM
May-24-23 05:00AM
May-19-23 05:00AM
May-17-23 05:00AM
May-15-23 05:00AM
May-10-23 05:00AM
May-05-23 09:00AM
May-04-23 05:00AM
May-03-23 09:00AM
Apr-19-23 05:30PM
Apr-13-23 08:45PM
Mar-28-23 05:00AM
Mar-17-23 09:10AM
Mar-01-23 04:30PM
Feb-27-23 07:15PM
Feb-14-23 04:01PM
Feb-10-23 04:01PM
Feb-09-23 02:30AM
Feb-06-23 04:00AM
Jan-24-23 04:00AM
Jan-23-23 03:25AM
Jan-13-23 04:00AM
Jan-11-23 04:00AM
Jan-06-23 07:00AM
Dec-22-22 04:00AM
Dec-16-22 06:45AM
Dec-08-22 03:30AM
Dec-07-22 04:00AM
Dec-02-22 10:41AM
Dec-01-22 05:00PM
Nov-30-22 02:47PM
Nov-16-22 07:27AM
Nov-14-22 02:00AM
Nov-10-22 04:00AM
Oct-27-22 05:00PM
Oct-26-22 05:00PM
Oct-19-22 08:38PM
Oct-17-22 05:00AM
Oct-11-22 05:00PM
Sep-22-22 08:00AM
Sep-05-22 05:00AM
Aug-31-22 05:00PM
Aug-29-22 04:00AM
Aug-25-22 04:00AM
Aug-24-22 04:00AM
Aug-15-22 04:00AM
Aug-12-22 04:00AM
Aug-08-22 12:17PM
Jul-20-22 08:00AM
Jul-14-22 08:00AM
Jul-07-22 11:28AM
Jul-05-22 04:56AM
Jun-27-22 09:17AM
Jun-22-22 06:56PM
Jun-21-22 04:38AM
Jun-15-22 04:01PM
Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines. It operates through the following geographical segments: North America, Europe, Asia, and Other. The company was founded by Robert Wessman on August 23, 2021 and is headquartered in Luxembourg.